Real-world Tactics to Address Health Inequities in Multiple Myeloma Care

This activity is part of a series


Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), Phoenix, AZ
Chief Medical Officer, International Myeloma Foundation (IMF), Studio City, CA
Joseph Mikhael, MD, MEd, FRCPC, FACP

Dr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He is also the Chief Medical Officer of the International Myeloma Foundation (IMF).

Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute where he conducts phase 1 clinical trials. He also serves as a Councilor on the Executive of the American Society of Hematology. Dr. Mikhael is the Chair of the Diversity, Equity and Inclusion Council for TGen.

Dr. Mikhael was recently a hematologist at Mayo Clinic Arizona where he served as a Professor at the Mayo College of Medicine, Associate Dean of Graduate Medical Education and Deputy Director – Education of the Mayo Clinic Cancer Center. He has been recognized with numerous awards in education including being in the Mayo Clinic Resident and Fellow Association Hall of Fame as Educator of the Year. He was also recently named in the Top 100 Doctors in the United States.

Dr. Mikhael did his initial medical school training in Ottawa, Canada, followed by his Hematology Residency at Princess Margaret Hospital in Toronto. He then did a Multiple Myeloma Fellowship there along with a Masters’ Degree in Education from the University of Toronto. He was on staff at PMH until being recruited to Mayo Clinic in 2008.

He specializes clinically in plasma cell disorders, namely multiple myeloma, amyloidosis and Waldenstrom’s macroglobulinemia. Dr. Mikhael is currently the principal investigator of many clinical trials, primarily in multiple myeloma. His other clinical research interests also include pharmaco-economics, communication skills and media relations. He has published over 150 peer reviewed articles in these fields. He lectures internationally on a regular basis. He is an active member of the International Myeloma Working Group and led the first ever ASCO Guidelines for Multiple Myeloma.

Dr. Mikhael leads the diversity efforts of the IMF, known as the M-Power program, seeking to empower patients and communities change the course of myeloma in at risk populations. He is also leading the IMF African American initiative whose goal is to improve the outcomes and care delivered to African Americans with myeloma; a disease with double the incidence in African Americans than Caucasians. Dr. Mikhael also spends about 20% of his time in the third world seeking ways to enhance research, collaboration and access to myeloma therapies in underprivileged countries.

Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service, New York, NY
Chief of Myeloma Service
Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK)
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT, New York, NY
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service, New York, NY

Saad Zafar Usmani, MD, MBA, FACP, received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. In 2010, Dr. Usmani joined the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, as the Director of Developmental Therapeutics and Assistant Professor of Medicine. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies, where he built an internationally-renowned myeloma program. He now serves as the Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center (MSKCC).

Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group (IMF), Alliance Myeloma Committee (Chair), American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), American Society for Transplantation & Cellular Therapy (ASTCT), and National Cancer Institute (NCI) Myeloma Steering Committee (MYSC). Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, Chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and Chair for the ASCO Scientific Committee on Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, Controversies in Multiple Myeloma (COMy) Award for Excellence in Myeloma Research, Leukemia and Lymphoma Society (LLS) Scholar in Clinical Research Award, and International Myeloma Society Bart Barlogie Young Investigator Award for clinical and translational research. Dr. Usmani has authored/co-authored more than 210 peer-reviewed research manuscripts and 250 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani’s research interests focus on plasma cell disorders, in particular, high-risk multiple myeloma.

Statement of Need

Multiple myeloma has twice the incidence and death rate in Black people, compared with White people. Yet, Black people are half as likely to undergo a stem cell transplantation despite having similar, if not better, survival rates compared to White people, when given standard of care treatment. Chasms in early diagnosis, treatment options and access, survival rate, and more, remain for racial and ethnic underserved populations. A culmination of biases, disparities, and inequities continues a cycle of inadequate oncology treatment for multiple myeloma, thus resulting in delayed diagnosis and suboptimal clinical management, prognosis, and survival rate.

In this CME Outfitters BriefCase, faculty experts will guide learners through a patient case scenario reflecting the impact of biases, disparities, and health inequities that reduce the quality of oncology care for racial and ethnic underserved patients with multiple myeloma. This program will provide actionable strategies, empowering attendees to recognize factors and implement changes in practice to improve multiple myeloma treatment.

Learning Objectives

At the end of this CME/CE activity, participants should be able to identify the impact of health inequities on patients with multiple myeloma and develop individual treatment strategies for optimal outcomes.

Financial Support

Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), nurses/nurse navigators, pharmacists, and dieticians specializing in hematology, pathology, radiology, or primary care

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.5 contact hours.

Note for California Nurses

This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-22-136-H01-P

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Dietetics (CDR)

Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Log. Performance indicator selection is at the learner’s discretion.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

Dr. Mikhael reports the following financial relationships:

Consultant: Amgen Inc.; Bristol Myers Squibb; GSK; Janssen Pharmaceuticals, Inc.; Karyopharm; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Usmani reports the following financial relationships:

Advisory Board: AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; EdoPharma; Genentech, Inc.; Gilead Sciences, Inc.; GSK; Janssen Pharmaceuticals, Inc.; Oncopeptides, Inc.; Sanofi; Seattle Genetics, Inc.; Secura Bio; SkylineDx USA, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Teneobio, Inc.

Research Support: Amgen Inc.; Array BioPharma Inc.; Bristol Myers Squibb Company; Celgene Corporation; GSK; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pharmacyclics, Inc.; Sanofi; Seattle Genetics, Inc.; SkylineDx USA, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: Amgen Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Sanofi

The following peer reviewer and CME Outfitters staff have no financial relationships:

  • Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
  • Meghann Taft-Lockard (planning committee)
  • David Modrak, PhD (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sharon Tordoff (planning committee)

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.



Real-world Tactics to Address Health Inequities in Multiple Myeloma Care
Event Date: 10/17/2022 at 4:00 am EST